Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio™ with The Stock Day Podcast

<div>The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (TRVI) (“the Company”), a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with IPF, other chronic cough indications, and for the treatment of prurigo nodularis. President and CEO of the Company, Jennifer Good, joined Stock Day host Everett Jolly. </div>